To date, more than 100 clinical trials with human pluripotent stem cell (hPSC)-derived products have been initiated worldwide and an increasing number of potential hPSC-derived clinical products have entered early developmental pipelines. For off-the-shelf (allogeneic) products, the identification and selection of the right hPSC line early on during this process is of the utmost importance as failure to do so may delay or completely stall product development.
Researchers identify 166 human pluripotent stem cell lines available for use in clinical applications
